The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC ...

Panelists discuss how the new nilotinib formulation offers improved convenience by eliminating fasting requirements which may enhance adherence, while emphasizing that clinicians should remain ...

A nurse practitioner gives her advice for managing adverse events during treatment with talquetamab for multiple myeloma.

Panelists discuss the importance of using liquid biopsy for detecting estrogen receptor 1 (ESR1) mutations rather than ...

Panelists discuss how molecular testing and liquid biopsies are crucial for tracking estrogen receptor 1 (ESR1) mutations in ...

When Stable Disease Progresses: ESR1 Mutations at the Point Of Progression In Juliana’s Case ...

Traditionally, HER2 status has been determined by immunohistochemistry (IHC) and in situ hybridization (ISH), distinguishing ...

The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to ...

Retifanlimab-dlwr (Zynyz) has been granted approval from the FDA for treatment of locally recurrent or metastatic squamous ...

The extended injection time for subcutaneous daratumumab in those with myeloma can serve as an opportunity for oncology nurses to check in with patients.

Panelists discuss how managing common adverse events associated with tyrosine kinase inhibitors (TKIs) such as nilotinib ...

Panelists discuss how simpler treatment regimens with fewer restrictions, such as the new nilotinib formulation without ...